Loading
Nuvectis Pharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BENTSUR RON, was filed 01 Jul 2026.
Insider Decl.
180
Thresholds
n/a
Buy Volume
€9M
150 ops. · all time
Sell Volume
€20,945
1 ops. · all time
Who traded when
BuySaleMarlio Charles Mosseri23 buys
Ron Bentsur4 buys
Enrique Poradosu1 buy
Juan Sanchez1 buy
Matthew L. Kaplan1 buy
Michael J. Carson1 sale
Since the insiders bought
- -5.4%Entry US$19.57 · Close 16 Oct 2026 US$18.52
- +201.6%Entry US$6.14 · Close 16 Oct 2026 US$18.52
- +201.6%Entry US$6.14 · Close 16 Oct 2026 US$18.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.59
Analyst consensus
5 analysts1.33/5
US$30.00Target US$35.40(+72%)US$40.00
Income statement
EBITDA-US$27.6M
Net income-US$26.4M0.0% margin
Valuation
P/Book60.6x
Beta-0.24
Balance sheet & cash
Market capUS$672.1M
Free Cash Flow-US$16M
Profitability & ownership
ROE-214.6%
ROA-73.1%
% insiders34.4%
% institutions33.6%
Last declaration on 5 August 2026
Declarations180 total
30,000 shares0Common StockSEC:0001104659-26-091279:0
12,500 shares@ US$20.0011.2% of flowCommon StockSEC:0001104659-26-079792:0
Canonical exit: 28 Sept 2026 (T+90)
150,000 shares0Common StockSEC:0001104659-26-002501:0
150,000 shares0Common StockSEC:0001104659-26-002500:0
150,000 shares0Common StockSEC:0001104659-26-002497:0
61,200 shares0Common StockSEC:0001104659-26-002489:0
5,000 shares@ US$5.721.4% of flowCommon StockSEC:0001104659-25-107423:0
Canonical exit: 3 Feb 2026 (T+90)
13,000 shares@ US$5.79100.0% of flowCommon StockSEC:0001104659-25-107422:0
Canonical exit: 3 Feb 2026 (T+90)
11,000 shares@ US$5.8475.6% of flowCommon StockSEC:0001104659-25-107418:0
Canonical exit: 3 Feb 2026 (T+90)
30,000 shares0Common StockSEC:0001104659-25-104664:0
35,034 shares@ US$6.152.9% of flowCommon StockSEC:0001104659-25-103522:1
Canonical exit: 22 Jan 2026 (T+90)
72,836 shares@ US$6.286.2% of flowCommon StockSEC:0001104659-25-103522:2
Canonical exit: 25 Jan 2026 (T+90)
46,900 shares@ US$6.065.5% of flowCommon StockSEC:0001104659-25-103522:0
Canonical exit: 21 Jan 2026 (T+90)
5,603 shares@ US$7.990.9% of flowCommon StockSEC:0001104659-25-062168:0
Canonical exit: 18 Sept 2025 (T+90)
28,043 shares@ US$8.053.1% of flowCommon StockSEC:0001104659-25-060965:1
Canonical exit: 16 Sept 2025 (T+90)
5,399 shares@ US$8.110.9% of flowCommon StockSEC:0001104659-25-060965:0
Canonical exit: 15 Sept 2025 (T+90)
30,000 shares0Common StockSEC:0001104659-25-058919:0
30,000 shares0Common StockSEC:0001104659-25-058916:0
30,000 shares0Common StockSEC:0001104659-25-058915:0
21,167 shares@ US$8.113.5% of flowCommon StockSEC:0001104659-25-047938:0
Canonical exit: 10 Aug 2025 (T+90)
100 shares@ US$8.710.0% of flowCommon StockSEC:0001104659-25-047089:1
Canonical exit: 6 Aug 2025 (T+90)
2,400 shares@ US$8.970.3% of flowCommon StockSEC:0001104659-25-047089:2
Canonical exit: 6 Aug 2025 (T+90)
9,850 shares@ US$8.951.2% of flowCommon StockSEC:0001104659-25-047089:3
Canonical exit: 7 Aug 2025 (T+90)
9,817 shares@ US$8.901.2% of flowCommon StockSEC:0001104659-25-047089:4
Canonical exit: 7 Aug 2025 (T+90)
5,395 shares@ US$8.980.7% of flowCommon StockSEC:0001104659-25-047089:5
Canonical exit: 7 Aug 2025 (T+90)
25 of 180 declarations
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is one of the most purchase-heavy records: 150 purchases for EUR 9,192,156, with a median of EUR 11,237, and a single sale, EUR 20,945, by Michael J. Carson, Vice President, Finance, on November 7, 2024. Purchases make up 99% of open-market trades, in small repeated amounts. Ron Bentsur, Chairman & CEO, signs 81 of the 180 filings, 77 of them purchases and none a sale; the largest is EUR 874,450 on February 4, 2022. Marlio Charles Mosseri, 10% Owner, reported 43 purchases, including EUR 1,163,839 on June 23, 2023 and EUR 1,155,432 on February 7, 2025.
Between May 12 and May 27, 2022, five filers bought for EUR 490,153 in total. Across the full history, 101 purchase filings are classed as clustered. All 150 purchases have a stored 90-day result, with a median of minus 19.1% (stored results, not a forecast).
Read moreShow less
Shay Shemesh, Chief Dev. & Ops. Officer, has 23 filings, 18 of them purchases, Enrique Poradosu, Chief Science & Business Off, 12 with 7. The record gathers 9 filers and 29 grants, from February 4, 2022 to August 3, 2026, with 69 filings in 2022 and 6 in 2026. Over the last twelve months: 13 filings, 7 of them purchases.
